Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Berglund

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal for Immunotherapy of Cancer|November 12, 2020
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratioErika J Crosby, Amy C Hobeika, Donna Niedzwiecki, et al.
Journal of the American Chemical Society|May 10, 2012
Rendering protein-based particles transiently insoluble for therapeutic applicationsJing Xu, Jin Wang, J Christopher Luft, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2012
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effectsTakuya Osada, Peter Berglund, Michael A Morse, et al.
Biorxiv : the Preprint Server for Biology|December 21, 2021
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concernDavid W Hawman, Kimberly Meade-White, Jacob Archer, et al.
Elife|February 22, 2022
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concernDavid W Hawman, Kimberly Meade-White, Jacob Archer, et al.
Science Translational Medicine|August 7, 2024
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical modelsNikole L Warner, Jacob Archer, Stephanie Park, et al.
Vaccine|October 27, 2007
Development and preclinical evaluation of an alphavirus replicon vaccine for influenzaBolyn Hubby, Todd Talarico, Maureen Maughan, et al.
Vaccines|November 27, 2021
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An OverviewBruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes Dos Santos Fonseca, et al.
Iscience|April 15, 2025
Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaquesSevasti Karaliota, Maha Moussa, Margherita Rosati, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2023
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammationTaishi Kimura, Joseph M Leal, Adrian Simpson, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|November 12, 2020
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratioErika J Crosby, Amy C Hobeika, Donna Niedzwiecki, et al.
Journal of the American Chemical Society|May 10, 2012
Rendering protein-based particles transiently insoluble for therapeutic applicationsJing Xu, Jin Wang, J Christopher Luft, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2012
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effectsTakuya Osada, Peter Berglund, Michael A Morse, et al.
Biorxiv : the Preprint Server for Biology|December 21, 2021
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concernDavid W Hawman, Kimberly Meade-White, Jacob Archer, et al.
Elife|February 22, 2022
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concernDavid W Hawman, Kimberly Meade-White, Jacob Archer, et al.
Science Translational Medicine|August 7, 2024
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical modelsNikole L Warner, Jacob Archer, Stephanie Park, et al.
Vaccine|October 27, 2007
Development and preclinical evaluation of an alphavirus replicon vaccine for influenzaBolyn Hubby, Todd Talarico, Maureen Maughan, et al.
Vaccines|November 27, 2021
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An OverviewBruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes Dos Santos Fonseca, et al.
Iscience|April 15, 2025
Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaquesSevasti Karaliota, Maha Moussa, Margherita Rosati, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2023
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammationTaishi Kimura, Joseph M Leal, Adrian Simpson, et al.
Pageof 5